Search Results - "Phillips Jr, Eli G"

  • Showing 1 - 9 results of 9
Refine Results
  1. 1

    Real-world adverse events associated with CAR T-cell therapy among adults age ≥ 65 years by Zettler, Marjorie E., Feinberg, Bruce A., Phillips Jr, Eli G., Klink, Andrew J., Mehta, Sonam, Gajra, Ajeet

    Published in Journal of geriatric oncology (01-03-2021)
    “…Chimeric antigen receptor (CAR) T-cell therapy has emerged as a promising treatment for relapsed or refractory large B-cell lymphoma (LBCL) with the Food and…”
    Get full text
    Journal Article
  2. 2

    Neurological adverse events following CAR T-cell therapy: a real-world analysis by Gajra, Ajeet, Zettler, Marjorie E, Phillips Jr, Eli G, Klink, Andrew J, Jonathan K Kish, Fortier, Stephanie, Mehta, Sonam, Feinberg, Bruce A

    Published in Immunotherapy (01-10-2020)
    “…To characterize real-world neurological adverse events (AEs) associated with chimeric antigen receptor T-cell therapies in patients with refractory/relapsed…”
    Get full text
    Journal Article
  3. 3
  4. 4

    Use of Real-World Evidence to Support FDA Approval of Oncology Drugs by Feinberg, Bruce A., Gajra, Ajeet, Zettler, Marjorie E., Phillips, Todd D., Phillips, Eli G., Kish, Jonathan K.

    Published in Value in health (01-10-2020)
    “…Real-world evidence (RWE) has gained increased attention in recent years as a complement to traditional clinical trials. The use of RWE to establish the…”
    Get full text
    Journal Article
  5. 5

    Neurological Adverse Events Following CAR-T Cell Therapy: A Real-World Analysis of Adult Patients Treated with Axicabtagene Ciloleucel or Tisagenlecleucel by Gajra, Ajeet, Zettler, Marjorie E, Phillips Jr, Eli G, Klink, Andrew J, Kish, Jonathan K., Mehta, Sonam, Feinberg, Bruce

    Published in Blood (13-11-2019)
    “…Introduction: Neurotoxicity is a major adverse event (AE) of CAR-T therapy with diverse presentation. When severe, it can be fatal, and may lead to neurologic…”
    Get full text
    Journal Article
  6. 6

    Real-World Analysis of Adverse Events Associated with CAR T-Cell Therapy Among Adults Age ≥65 Years by Zettler, Marjorie E, Feinberg, Bruce A, Phillips Jr, Eli G, Klink, Andrew J, Mehta, Sonam, Gajra, Ajeet

    Published in Blood (13-11-2019)
    “…Introduction: Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tis-cel) are chimeric antigen receptor (CAR) T-cell therapies that target CD19-expressing…”
    Get full text
    Journal Article
  7. 7

    The gamification of healthcare: emergence of the digital practitioner? by Phillips, Jr, Eli G, Nabhan, Chadi, Feinberg, Bruce A

    Published in The American journal of managed care (01-01-2019)
    “…The application of behavioral economics principles in healthcare has been transformed through the use of technology and recently the advent of video gaming…”
    Get full text
    Journal Article
  8. 8

    Expanded Access and Right To Try Requests: The Community Oncologist's Experience by Zettler, Marjorie E, Jeune-Smith, Yolaine, Feinberg, Bruce A, Phillips, Jr, Eli G, Gajra, Ajeet

    Published in JCO oncology practice (01-11-2021)
    “…For patients with cancer who have exhausted approved treatment options and for whom appropriate clinical trials are not available, access to investigational…”
    Get more information
    Journal Article
  9. 9

    Generic liability, or lack thereof, under duty-to-warn: it's all about the labeling by Smith, W. Thomas, Phillips, Eli G., Jr

    Published in The Health lawyer (01-12-2012)
    “…[...]there is very little reason to be concerned from a patient-health perspective that patients have little say in their use of generic drugs. [...]since the…”
    Get full text
    Magazine Article